Cell Stem Cell, published by CELL PRESS, is a premier journal at the forefront of cellular biology, genetics, and molecular medicine. With an esteemed impact factor and recognized as a Q1 journal in multiple categories including Cell Biology, Genetics, and Molecular Medicine, it offers researchers, professionals, and students rigorous, peer-reviewed articles that shape the future of stem cell research and regenerative medicine. Located in Cambridge, MA, this journal has become an invaluable resource since its inception in 2007 and is committed to disseminating groundbreaking findings that drive innovation and understanding in these critical fields. By consistently ranking within the top percentile of its categories in Scopus, Cell Stem Cell remains an essential platform for scholarly communication, fostering collaboration among leading scientists worldwide. Although the journal does not currently offer open access options, its comprehensive insights are pivotal for anyone engaged in the study of stem cells and their applications.

The International Journal of Stem Cells is a distinguished peer-reviewed journal dedicated to advancing the field of stem cell research. Published by the Korean Society for Stem Cell Research, this journal has established itself as a vital source of high-quality research since its inception in 2008. Operating under the ISSN 2005-3606 and E-ISSN 2005-5447, the journal caters to a global audience, featuring works that span a diverse array of topics within Cell Biology and Developmental Biology. It is noteworthy that as of 2023, the journal is ranked Q3 in Cell Biology and Q2 in Developmental Biology, highlighting its growing influence and credibility in the scientific community. Given its commitment to facilitating open scientific communication, it is crucial for researchers, professionals, and students to engage with the rigorous research published in this journal as it profoundly impacts the understanding and application of stem cell science. With accessibility to a wealth of innovative studies, the International Journal of Stem Cells remains an indispensable resource for anyone interested in the transformative potential of stem cell research.

INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, published by Wiley, is a leading peer-reviewed journal dedicated to the field of experimental pathology. With an ISSN of 0959-9673 and E-ISSN 1365-2613, the journal has been a vital resource for researchers and professionals since its inception in 1990, covering a broad spectrum of topics within pathology, cell biology, and molecular biology. The journal's relevancy is underscored by its Q2 ranking in Pathology and Forensic Medicine and Q3 rankings in both Cell Biology and Molecular Biology, as of 2023, reflecting its significant contribution to the scientific community. Although it does not currently offer open access options, readers can benefit from its insightful research articles and reviews that guide advancements in diagnostic pathology and therapeutic strategies. As the journal continues to evolve, it remains committed to facilitating the exchange of innovative ideas and findings that drive progress in experimental pathology and related fields, making it an indispensable platform for scientists, clinicians, and students alike.

Regenerative Medicine, published by Taylor & Francis Ltd, is a pivotal journal within the field of biomedical research, focusing on the innovative advances in regenerative and restored functions in human health. With an ISSN of 1746-0751 and an E-ISSN of 1746-076X, this esteemed journal boasts a commendable impact factor within its categories, notably holding the Q2 status in Embryology and Q3 in Biomedical Engineering as of 2023. Covering a broad spectrum of topics from stem cell research to tissue engineering, it serves as a crucial platform for interdisciplinary collaboration among researchers, professionals, and students dedicated to the regeneration of tissues and organs. Given its comprehensive scope from 2006 to 2024, the journal continues to attract high-quality manuscripts that advance the frontiers of knowledge in regenerative medicine. Researchers and practitioners alike are encouraged to engage with the latest findings and methodologies disseminated in this vital publication.

Organogenesis is a leading journal published by Taylor & Francis Inc, dedicated to advancing the field of developmental biology and regenerative medicine. With an ISSN of 1547-6278 and E-ISSN 1555-8592, this journal spans an extensive research scope that includes embryology, transplantation, and biomedical engineering, distinguishing itself as a crucial platform for researchers and practitioners alike. Its impact is reflected in its performance across various categories in 2023, earning Q3 rankings in Biomedical Engineering and Embryology, Q4 in Developmental Biology, and Q2 in Transplantation, showcasing its reputable standing among peer journals. Moreover, with Scopus rankings indicating strong positioning in the fields of medicine and biochemistry, Organogenesis is essential for those looking to publish or stay updated on pioneering research. The journal facilitates rigorous peer-review and offers a forum for disseminating innovative findings, making it an invaluable resource for academics, professionals, and students committed to understanding the complexities of organism development.

NATURE REVIEWS MOLECULAR CELL BIOLOGY, published by NATURE PORTFOLIO, stands as a seminal journal in the fields of cell and molecular biology, with a significant impact factor that underscores its influence and reputation within the scientific community. Established in 2000 and continuing its legacy into 2024, this journal delivers comprehensive reviews that synthesize current knowledge and advancements in molecular and cellular processes. Respected for its high-quality articles, it has maintained a prestigious Q1 ranking in both Cell Biology and Molecular Biology categories as of 2023. With an exceptional Scopus ranking, taking the top position in its category, it attracts a readership of prominent researchers, professionals, and students eager to stay abreast of groundbreaking discoveries and methodologies. Although it does not offer Open Access, subscribers benefit from exclusive access to vital insights that foster innovative research approaches and advancements in the life sciences. The journal’s objective is to bridge the gap between research and application, providing indispensable resources to its audience while contributing to the global conversation on molecular and cellular biology.

Tissue Engineering Part A is a prestigious peer-reviewed journal published by MARY ANN LIEBERT, INC that focuses on innovative research and advancements within the field of tissue engineering and regenerative medicine. Since its inception in 2008, this journal has played a critical role in disseminating cutting-edge findings that bridge the gap between laboratory research and clinical application, underscoring its significance in the scientific community. With a diverse scope encompassing biochemistry, bioengineering, biomaterials, and biomedical engineering, the journal ranks notably in the Scopus database, holding a Q2 quartile status across multiple categories, thus reflecting its high impact on ongoing research and professional practice. For researchers, professionals, and students, Tissue Engineering Part A serves as an invaluable resource, offering insights into the latest methodologies and breakthroughs that drive the future of healthcare and therapeutic strategies. While primarily a subscription-based journal, it ensures that vital research is accessible to a broad audience of scientists and engineers committed to advancing the life sciences.

DEVELOPMENT is a preeminent journal published by COMPANY BIOLOGISTS LTD, headquartered in the United Kingdom. With an ISSN of 0950-1991 and an E-ISSN of 1477-9129, this esteemed journal has been at the forefront of the fields of Developmental Biology and Molecular Biology since its inception in 1987. Recognized for its rigorous peer review process and high-caliber research, DEVELOPMENT holds an impressive Q1 ranking in both disciplines as of 2023, underscoring its pivotal role in advancing scientific understanding. The journal is particularly noted for its contributions to the understanding of developmental processes, their molecular underpinnings, and their implications in health and disease. With a significant impact factor, DEVELOPMENT aims to disseminate groundbreaking research that inspires novel insights and future explorations within the biological sciences, making it an essential resource for researchers, professionals, and students alike. The journal also maintains accessibility for its readership, ensuring that significant research findings reach those who can apply and build upon them.

JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS, published by Wiley, is a leading journal in the field of biomaterials and biomedical engineering, with an impact factor reflected in its relevant Scopus rankings—including a Q2 position in Biomedical Engineering and Q3 in Biomaterials for 2023. This journal, with ISSN 1552-4973 and E-ISSN 1552-4981, serves as a vital platform for disseminating pioneering research and innovative applications of biomaterials. Positioned in the United States, it aims to bridge the gap between material science and biological applications, fostering collaboration among researchers, professionals, and students dedicated to advancing technology in healthcare. With a convergence of studies from 2003 to 2024 and a growing focus on open access, the journal ensures greater visibility and accessibility for groundbreaking research. Join us in exploring the dynamic field of biomaterials, as we push the boundaries of science and engineering for improved patient outcomes.

CELL AND TISSUE BANKING, published by Springer, is a prominent journal dedicated to advancing the fields of biomaterials, biomedical engineering, cell biology, and transplantation. With its ISSN 1389-9333 and E-ISSN 1573-6814, the journal plays a crucial role in disseminating high-quality research from its inception in 2000 to its ongoing contributions through 2024. Situated in the Netherlands, it boasts a respectable 2023 impact factor with notable quartile rankings, positioning it within the Q3 category for biomaterials, biomedical engineering, and transplantation, and Q4 for cell biology. Furthermore, its Scopus rankings underscore its relevance and influence, particularly in the fields of medicine and engineering. Although it does not currently offer open access options, the journal remains a vital resource for researchers, professionals, and students alike, fostering innovation and knowledge transfer in the critical areas of cell and tissue sustainability.